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Abstract
Background
Herpesviruses induce a range of inflammatory effects potentially contributing to an
increased risk of stroke.
Objectives
To investigate whether patients with infection, or reactivation of, human herpesviruses are
at increased stroke risk, compared to those without human herpesviruses.
Data sources
Six medical databases and grey literature sources from inception to January 2017.
Study eligibility criteria
Studies where the exposure was any human herpesvirus and the outcome was stroke. We
included randomised controlled trials, cohort, case-control, case-crossover and self-con-
trolled case series designs.
Methods
Meta-analyses when sufficiently homogeneous studies were available. Quality of evidence
across studies was assessed.
Results
We identified 5012 publications; 41 met the eligibility criteria. Across cohort and self-con-
trolled case series studies, there was moderate quality evidence that varicella infection in
children was associated with a short-term increased stroke risk. Zoster was associated with
a 1.5-fold increased stroke risk four weeks following onset (summary estimate: 1.55, 95%CI
1.46–1.65), which resolved after one year. Subgroup analyses suggested post-zoster stroke
risk was greater among ophthalmic zoster patients, younger individuals and those not
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prescribed antivirals. Recent infection/reactivation of cytomegalovirus and herpes simplex
viruses, but not past infection, was associated with increased stroke risk; however the evi-
dence across studies was mainly derived from small, very low quality case-control studies.
Conclusions
Our review shows an increased stroke risk following zoster and suggests that recent infec-
tion or reactivation of other herpesviruses increases stroke risk, although better evidence is
needed. Herpesviruses are common and potentially preventable; these findings may have
implications for reducing stroke burden.
Introduction
Globally, stroke is the second most frequent cause of death.[1] There is a growing literature
indicating that infections, particularly acute respiratory and urinary infections, may play a role
in triggering vascular events.[2] Herpesviruses are a family of common viruses persisting
latently after primary infection and reactivating periodically. The viruses induce a range of
inflammatory effects,[2] potentially contributing to thrombogenesis, atherosclerosis, vasculo-
pathy and platelet activation and thus an increased risk of stroke.
Six previous reviews support an association between herpes zoster (caused by the reactiva-
tion of varicella zoster virus (VZV)) and stroke.[3–8] One reported a risk ratio of 1.36 (95%CI
1.10–1.67) for the association between zoster and stroke pooled across six cohort studies,[4]
whilst the other reviews found around 2-fold increased risk shortly after zoster, which
decreased over the following year.[3, 5–7] Cytomegalovirus (CMV) is also hypothesised to
modulate stroke risk, especially among immunocompromised populations[9] and a recent sys-
tematic review concluded that cytomegalovirus infection is associated with an increased risk of
cardiovascular disease.[10]
Although these reviews have made a significant contribution, there are certain limitations,
such as; exclusion of self-controlled case series (SCCS),[4] exclusion of studies among chil-
dren,[3–8] limited subgroup analyses (only one study assessed whether antiviral therapy modi-
fied stroke risk)[7] and restricted scope by looking exclusively at clinically apparent zoster and
stroke risk. Studies assessing any of the eight herpesviruses known to infect humans and utilis-
ing laboratory tests and serological analysis, as well as clinical diagnoses, could also help eluci-
date the role of latent, sub-clinical or clinical infection and stroke risk.
The primary objective of the systematic review was therefore to investigate whether patients
with infection, or reactivation of, human herpesviruses are at increased risk of stroke,
Methods
The protocol was published[11] according to the Preferred Reporting Items for Systematic
Reviews and Meta Analyses Protocols guidelines (PROSPERO registration number:
CRD42017054502).
Study designs and characteristics
Eligible study designs included cohort, case-control, case-cohort, case-crossover and SCCS
designs. Randomised controlled trials investigating prevention or treatment of herpesvirus
infection or reactivation (using vaccines or antiviral agents) were also eligible. We excluded
Herpesviruses and stroke
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cross-sectional studies, ecological studies, case-series, case-reports and reviews. Studies were
required to report an effect estimate or the data that allow its calculation. We placed no restric-
tions on time period, publication status, language, geographical setting or healthcare setting.
Participants
Eligible studies included human participants. No restrictions were placed participants’ on age
or immunosuppression status.
Exposure
The exposures of interest were infection with, or reactivation of, the eight human herpesvi-
ruses: specifically, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), VZV, Epstein-Barr
virus (EBV), CMV, herpesvirus 6, 7, and 8. The exposure definition could be self-reported or a
confirmed diagnosis, either through clinical or laboratory criteria. Vaccination against herpes-
viruses (e.g. Zostavax vaccine) and treatment for herpesviruses (e.g. antivirals) were also con-
sidered as effect modifiers, to investigate whether preventing or treating human herpesviruses
attenuated stroke risk.
Comparators
Eligible studies were required to include a comparison group of people (or person time for
SCCSs or case-crossover) without the herpesvirus exposure of interest.
Outcomes
Studies were included if stroke (first ever or subsequent) was an outcome, clinically diagnosed
or self-reported. Those studies meeting the inclusion criteria were additionally assessed for
secondary outcomes: TIA[12] and subtypes of stroke (ischaemic versus haemorrhagic).
Information sources
We searched for eligible articles in six databases, originally from dates of inception to January
2017, and then again in July 2018 limited to the years 2017 and 2018. The databases included
Cochrane Central Register of Controlled Trials, Embase, Global Health, Medline, Scopus and
Web of Science. We additionally searched the clinical trials registers (ClinicalTrials.gov) and
grey literature sources, including the New York Academy of Medicine Grey Literature Report
(www.greylit.org) and the Electronic Theses Online Service through the British Library
(http://ethos.bl.uk).
Search strategy
We searched medical subject heading terms and free text (in the title and abstract) for the con-
cepts ‘human herpesviruses’ and ‘stroke’ (combined with the Boolean logic operator AND).
Search terms were developed for the database Medline, reviewed by all collaborators and sub-
sequently transcribed into search terms for the remaining databases (supplementary informa-
tion S1 Appendix for search terms). Reference lists of eligible articles and relevant reviews
were scanned for additional papers.
Study selection
Eligibility assessment was performed independently in a blinded standardized manner by two
reviewers (CWG and HF); all retrieved titles and abstracts were screened.
Herpesviruses and stroke
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Data collection process
Data were extracted using a pre-defined standardised template. Extraction criteria were based
on the PICOS[13] (Population, Intervention, Comparator, Outcomes and Study design)
framework. As this is an aetiological study, “exposure” replaced “intervention” and “study
characteristics” broadened to “study design” (S3 Appendix for all items extracted). We also
recorded: the most fully adjusted effect estimates (odds ratios, hazard ratios, incidence rate
ratios, risk ratios) for the association between the exposure and stroke; confounders adjusted
for; and results of additional analyses relevant to our non-primary objectives. If there were no
events in one arm of the study, a continuity correction was applied (adding 0.5 to each cell
[13]).
Risk of bias in individual studies
Two authors independently assessed risk of bias in three studies and HF completed the
remaining studies. In keeping with the Cochrane Collaborations approach,[14–16] a pre-speci-
fied set of domains were considered, including bias due to: 1) confounding; 2) selection of par-
ticipants; 3) differential and non-differential misclassification of exposure and outcome; 4)
missing data; and 5) reverse causation. For each domain, a-priori criteria were set-out to assign
‘high’, ‘low’, ‘moderate’, or ‘unclear’ risk. A summary risk of bias table was produced; when a
domain had more than one item the highest risk of bias judgment was used (unless the only
item at high-risk was non-differential misclassification, which would bias results toward the
null).
Synthesis of results
We synthesised the results into a narrative, grouping studies by herpesvirus exposure and
study design; subgroup analyses were also described. We classified exposures as past infection
or recent infection/reactivation. IgM and IgA antibodies, and DNA, are present in the blood
for a limited period following herpesviruses exposure, therefore their presence suggests recent
infection or reactivation (though IgM has poor sensitivity for detecting acute infections and
poor specificity in immunosuppressed).[17] Conversely, IgG antibodies, although also raised
during an acute infection or reactivation, remain during latent infection, therefore were classi-
fied as a past infection.[17] We also presented results from studies of high versus low IgG titre,
as high IgG titre may reflect recent reactivation.
When at least two studies assessed the same herpesvirus as a stroke risk factor, meta-analy-
sis was considered. For pooling, we required studies to have identical study designs, the same
measurement for the herpesvirus (e.g. IgG seropositivity) and identify the outcome within a
similar time-frame. We pooled effect sizes (referred to as “summary estimates”) irrespective of
the type of effect estimate, due to stroke being rare. Random effects meta-analysis was used
throughout, to ensure a consistent approach to all analyses was employed; the I2 statistic indi-
cated moderate heterogeneity (I2>25%) for many subgroups. We investigated sources of het-
erogeneity (where there were at least three studies in the meta-analysis) by removing studies at
high-risk of bias.
Quality of the evidence
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE)[18]
approach was used to summarise the quality of cumulative evidence for each herpesvirus on
stroke. Evidence was categorised as ‘high’, ‘moderate’, ‘low’ or ‘very low’ quality, with observa-
tional studies starting as ‘low’; five reasons to rate down and three reasons to rate up the quality
Herpesviruses and stroke
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of evidence, were then considered.[19] Full criteria for grading is in S4 Appendix. We assessed
publication bias when there were at least 10 studies by creating a funnel plot: effect estimates
for the exposure on stroke risk were plotted against standard errors of the log odds, and sym-
metry was assessed visually and using Begg’s test for small-study effects.[20]
Ethics
As this is a systematic review, ethical approval is not required.
Results
In our initial search 5012 titles and abstracts were screened and 41 observational studies were
selected for review (Fig 1). Our updated search retrieved 607 studies, of which seven were
selected for review, making a total of 48 studies for the final review.
Study methods and results are summarised in Tables 1 and 2 respectively, risk of bias for
individual studies in Table 3 (S5 Appendix for detailed justification) and GRADE assessment
in Table 4. Results and meta-analyses are displayed in Figs 2–4.
17 studies assessed the association between zoster and stroke (1 case-control study,[21] 13
cohort studies[22–34] and 3 SCCS[35–37]) (Table 1). Ten were based in the US or Europe and
six in Asia and one in the Middle East; all studies used routinely collected medical records.
Two studies involved an immunosuppressed population. 8/17 studies were considered at low-
risk of bias in all domains.
Fig 1. Flow diagram of study selection.
https://doi.org/10.1371/journal.pone.0206163.g001
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Table 1. Study characteristics.
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
VZV reactivation—Herpes zoster
Breuer, 2014
[22]
Cohort 2002–2010 UK, primary
care records
from THIN
Adults (�18 yr) with
HZ and age (± 2 yr),
sex and GP practice
matched (2:1)
patients with no HZ.
Non-recurrent HZ:
Read codes
Patients
without an HZ
Read code
Primary: stroke or
TIA
Secondary:
ischaemic,
haemorrhagic or
unspecified stroke
First ever incident
stroke or TIA: Read
codes
Calabrese, 2017
[23]
Cohort 2006–2013 United States,
Medicare claims
data
Adults�65 yr with
HZ,�12mo follow-
up at entry,
inflammatory disease
(ankylosing
spondylitis/ IBD/
psoriasis/ psoriatic
arthritis/RA), no
prior stroke or
antiviral therapy
Inpatient/
outpatient HZ:
ICD-9 diagnosis
code AND no same
day code for zoster
vaccine
Time after HZ
divided into 3
periods: 0–90
days; 91–365
days; 366–730
days (reference
group).
Primary: Any
stroke
Secondary:
ischaemic stroke
Hospitalised stroke:
ICD-9 diagnosis
code in any position
on hospital claim.
Hosamirudsari,
2018 [21]
Case-
control
2015–2017 Iran, individuals
attending a
single hospital
Adults (aged 30–90
years) admitted for
stroke, and controls
were stroke-free
individuals
Self-reported HZ
infection in the last
6 months, collected
by a team of
healthcare
specialists.
No self-report
of HZ infection
Stroke Stroke diagnosed by
neurologist and
confirmed by brain
imaging
Kang, 2009[24] Cohort 1997–2001 Taiwan,
National Health
Research
Institute claims
database
Patients (�18 yr)
with HZ and no
history of stroke,
matched to 3 patients
(age, sex) with no
history of HZ or
stroke before 2001.
Treatment for HZ
in ambulatory care:
ICD-9 codes.
Patients
without a
history of HZ
Primary: stroke
(any)
Secondary:
ischaemic,
haemorrhagic
ICD-9 codes
Kim, 2017[32] Cohort 2002–2013 Korea, sample of
national health
insurance
database
Patients (age
unknown) with HZ
propensity score
matched to those
without HZ.
HZ diagnosis: ICD-
10 codes
Patients
without HZ
Stroke Newly diagnosed
stroke: ICD-10
codes
Kwon, 2016[25] Cohort 2003–2013 Korea, 1 million
sample of
national health
insurance
database
All patients (>18 yr)
in database: those
with HZ or stroke
during 1st yr of
observation period
excluded.
First HZ in the
observation period:
ascertained from
ICD-10 codes.
Patients
without a
history of HZ.
Stroke/TIA First ever stroke or
TIA: ICD-10 codes
Langan, 2014
[37]
SCCS 1987–
2012
UK, CPRD;
routinely
collected
database of
primary and
secondary care
records.
Adults (�18 yr) with
1st ever HZ and
stroke. Exclusions:
incident TIA,
subarachnoid
haemorrhage,
encephalitis in 12 mo
after stroke.
1st ever HZ: Read
and ICD-10 codes.
Exposed period:
day after HZ to 12
mo (wk 1–4, 5–12,
13–26, and 27–52).
All observation
time around
exposed
period, with
the exception
of the day of
HZ and 4-wk
pre-HZ
Primary: Arterial
stroke
Secondary:
cerebral
infarction,
haemorrhagic or
unspecified stroke
First ever stroke:
Read codes in
CPRD and ICD-10
codes in linked
hospital data.
Liao, 2017[33] Cohort 2000–2011 Taiwan,
National Health
Research
Institute claims
database
Adults (�18 yr) with
rheumatoid arthritis.
Those with HZ
matched (on age, sex,
disease duration) to
those without HZ.
Excluded those with
HZ or stroke prior to
entry
HZ diagnosis after
study entry: ICD-9
codes.
Patients
without HZ
Stroke ICD-9 codes
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
Lin, 2010[26] Cohort 2003–2005 Taiwan,
National Health
Research
Institute claims
database
Immunocompetent
adults (� 18 yr) with
HZO, matched (age,
gender) to 3 without
HZO. Excluded those
with stroke prior to
entry.
Patients seeking
ambulatory care for
HZO (patients with
HZO in the
previous yr
excluded: ICD-9
code (053.2)
Patients
without HZ.
First
ambulatory
care visit in
2004 was
assigned their
index date.
Stroke Not specified: most
likely from ICD-9
codes
Minassian, 2015
[35]
SCCS 2006–2011 United States,
Medicare claims
data
Patients (�65 yr)
with HZ and stroke /
TIA. Excluded if had
HZ or vascular events
pre-entry or
subarachnoid
haemorrhage ever or
encephalitis in 12 mo
post-stroke
HZ episode; ICD-9
code with antiviral
7 days before or
after HZ. Exposed
period: 12-mo after
HZ (wk 1, wk 2–4,
5–12, 13–26, and
27–52).
All other
observation
time made up
the baseline
(unexposed)
period, except
the day of and
the 4 wk before
HZ diagnosis.
Primary:
ischaemic stroke
Secondary:
haemorrhagic
stroke
Stroke: ICD-9 codes
in outpatient and
inpatient (primary
diagnostic field)
records
Patterson, 2018
[34]
Cohort 2007–2014 United States,
Medicare and
MarketScan data
Adults (> = 18) at
HZ diagnosis,
propensity matched
to HZ-free controls.
HZ diagnosis Patients
without HZ
Stroke and TIA Not specified: most
likely from ICD-9
codes
Schink, 2016
[36]
SCCS 2004–2011 Germany,health
claims data from
4 insurance
providers,
hospitalisations
and outpatients
data
Patients (any age)
with HZ and stroke,
�12 mo follow-up,
no history of stroke
or HZ in 12 mo pre-
cohort entry.
1st or recurrent HZ:
ICD-10 code or
antiviral with HZ
outpatient-
diagnosis. Exposed
period: up to 12 mo
from HZ (0–2 wk,
3–4 wk, 2–3 mo,
4–6 mo, 7–12 mo)
All follow-up
time outside
exposed
period.
Primary: First
stroke
Secondary:
ischaemic,
haemorrhagic,
stroke unspecified
or TIA.
Hospitalised stroke:
ICD-10 codes for
main discharge
diagnosis in
hospitalisation data.
Admission date
taken as onset date
Sreenivasan,
2013[27]
Cohort 1995–2008 Denmark,
routinely
collected civil
registration data
and health
registers.
All Danish adults
(�18 yr) alive during
study period. Persons
with outcome before
start of follow-up
were excluded.
HZ treated with
antivirals;
acyclovir
prescription (800
mg in packages of
35
tablets)
Cohort
members with
no prior
history of
acyclovir,
valacyclovir or
famciclovir
prescriptions.
Stroke and TIA
(as a composite
outcome)
ICD 8 and 10 codes,
from National
Patient Registry; a
database of all
hospitalisations,
outpatient visits and
emergency
department visits.
Sundstro¨m,
2015[28]
Cohort 2008–2010 Sweden,
routinely
collected
healthcare data
from one
county.
All incident cases of
HZ occurring during
the study period and
the general
population in the
country. No age
restrictions.
HZ from ICD-10
codes, with no
diagnosis of HZ in
the previous yr.
General
population in
the country (no
further
information
given).
Stroke ICD-10 diagnosis
within 1 yr of HZ
diagnosis.
Tseng, 2011[65] Cohort 2007–2010 United States,
Kaiser
Permanente
Southern
California health
care
HZ cases (�50 yr)
without history of
stroke 1 yr pre-HZ,
matched (age, date of
HZ, setting of
medical care) to
patients without HZ
HZ cases who had
received treatment
for HZ during the
study period
Patients
without HZ
Stroke Incident stroke,
identified from
hospitalisation
records with a
primary diagnosis
as stroke.
Yawn, 2016[31] Cohort 1986–2011 United States,
medical records
from Olmsted
County.
All adults (�50 yr)
with HZ, matched
(sex, age (+/- 1 yr)) to
patients without HZ.
Patients with history
of stroke excluded.
1st/recurrent HZ;
ICD-9 code and HZ
clinical symptoms
in medical records
Patients with
no HZ
diagnoses in
five yr prior to
cohort entry.
Stroke Diagnostic codes
from hospital
admissions or death
records, <30 days
before cohort entry,
or until cohort exit.
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
CMV infection
Coles, 2003[38] Case-
cohort
1995–1998 Australia,
Busselton
Health Survey,
and linked
hospital and
death data
Adults (40–89 yr)
developing stroke
and random sample
of non-stroke adults,
without CVD at
baseline, with serum
samples from 1981.
IgG antibodies:
avidity assay
(AxSym)
High level sample =
�250.
Participants
without IgG
antibodies to
CMV
Stroke First stroke; from
ICD-10 codes and
defined as either
admission to
hospital with any
diagnosis of stroke
or death from
stroke.
Fagerberg, 1999
[39]
Cohort 1987–1995 Sweden, men
from
intervention
study with
hypertension
and�1 other
CVD risk factor.
Men (50 to 72 yr). Of
508 recruited into
intervention study,
164 (32%) randomly
selected to participate
in sub-studies.
High IgG
antibodies: MEIA
on serological
samples taken at
entry and/or 3.5 yr
later. High titre
undefined
Participants
with low titres
against CMV.
Non-fatal stroke Independently
coded by 2
physicians using
hospital records,
autopsy records,
and death
certificates.
Gonza´lez-
Quijada, 2015
[40]
Case-
control
2011–2013 Spain, random
sample of
elderly patients
from a single
hospital
Cases (stroke
patients) and controls
(non-stroke patients)
aged�65 yr
(unmatched).
High IgG
antibodies: ELISA.
Defined as top
quartile of
serological values.
Date samples taken
unknown.
CMV
seropositive
participants
without high-
titre IgG
antibodies.
Ischaemic stroke
or TIA
Prevalent or
incident ischaemic
stroke and/or TIA:
determined by
imaging data or
neurology / internal
medicine
specialists.
Huang, 2012
[41]
Case-
control
1997–2000 China, Stroke
Hypertension
Investigation in
Genetics case-
control study
Stroke patients
matched to controls
without stroke (sex,
age ±3 yr, geographic
location, blood
pressure category.
Age unknown.
IgG, IgM
antibodies: ELISA
DNA: PCR on
plasma samples
taken after stroke
diagnosis (date
unknown).
Participants
without any
CMV infection
Primary: Any
stroke
Secondary:
ischaemic and
haemorrhagic.
Stroke patients
discharged from
hospital with stroke
in past 5 yr.
Diagnosed by
computer
tomography or
magnetic resonance
imaging
Kenina, 2010
[42]
Case-
control
Unclear Latvia, single
hospital. Data
collected
through clinical
evaluation and
questionnaires.
Stroke patients and
controls aged�42 yr.
IgG antibodies:
plasma and sera
using ELISA
Participants
without any
CMV infection
Primary:
ischaemic
Secondary:
Atherotrombotic,
Cardioembolic or
Undetermined
Stroke patients
hospitalised in the
Clinic of Neurology
Oliveras, 2003
[43]
Cohort 1979–2000 Spain, single
hospital. Data
collected
retrospectively.
Patients who received
renal transplants
between 1979–2000.
CMV infection
from medical
records: no further
information
provided
Participants
without any
CMV infection
Primary: Any
stroke
Secondary:
ischaemic and
haemorrhagic.
Diagnosis based on
clinical symptoms
and brain CT scan
or MRI.
Shen, 2011[44] Case-
control
2009 China,
inpatients and
outpatients from
neurology
department of
single hospital
Cases (aged�75
years) with cerebral
infarction and
controls with a
noraml carotid
ultrascan scan and
cerebral CT/MRI
scan.
IgM antibodies:
ELISA techniques
from serum
samples.
Participants
without any
CMV infection
Ischaemic stroke Diagnosis based on
the 1995 National
Cerebrovascular
Disease Meeting
standard for
cerebral infarction,
combined with a
CT/MRI scan.
Smieja, 2003
[45]
Cohort 1993–1995
(recruitment)
Canada,
multicentre
RCT among
patients with
history of CVD
Patients�55 yr with
blood samples
(N = 3168/9541).
Excluded those with;
MI/ stroke 4 wk
before study.
IgG antibodies:
quantitative CMV
IgG assay. Samples
taken at baseline.
Participants
with no
evidence of
CMV infection
Stroke (secondary
outcome)
Stroke was defined
as a neurologic
deficit lasting more
than 24 hours
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
Tarnacka, 2002
[46]
Case-
control
1998–1999 Poland, patients
with stroke
consecutively
admitted to
neurology
department.
Cases were patients
with stroke. Two
control groups; “old”
and “young,” no
clinical signs of
infection/ other
systemic diseases/
ischaemic stroke. All
had increased values
of serum IC
concentrations
Elevated levels of IC
containing anti-
CMV antibodies;
ELISA. Blood
samples taken <24
hrs and 7 to 30 days
after stroke onset.
Elevated levels
of IC not
containing
anti-CMV
antibodies
Ischaemic stroke Stroke within 24 hrs
after onset. CT
imaging,
sonography,
echocardiography,
and laboratory tests
confirmed the
diagnosis,
established from
history and
examination
Yi, 2008[47] Case-
control
Unclear China, no
further
information
Cases (�50 yrs) died
of stroke, matched
(age, sex) to controls
with no cerebro-
vascular disease,
CMV-associated
disease, immune
suppression, or IgG
for CMV.
DNA: immediate
early (IE) and late
(L) antigen in the
intracranial arteries
by PCR
Participants
without CMV
DNA
Ischaemic stroke Patients died of
ischaemic stroke.
Zheng, 2016
[48]
Case-
control
2004–2014 China, cohort
study within a
rural population
with
hypertension
Random sample of
stroke cases (�35 yr),
matched (age [1 yr],
sex, duration follow-
up, hypertension
stage) to controls
without stroke.
Patients with stroke
and CAD at baseline
excluded.
DNA: PCR on
blood samples
taken at
recruitment to
original cohort
study (prior to
stroke).
Participants
without CMV
DNA. A
negative result
meant no DNA
was detected.
Stroke First ever stroke
during follow-up:
evidence from
imaging data
extracted from
patients medical
records, and
independently
reviewed by the
end-point
assessment
committee.
Ziemann, 2016
[49]
Cohort 2008 Germany, trial
in patients
undergoing
cardiac surgery,
from single
hospital
Patients (�18 yr) due
for cardiac surgery:
those with planned
off-pump surgery
excluded. 195/1178
(16.6%) patients
excluded due to
inadequate blood
samples.
IgG antibodies:
CMIA
DNA: PCR, arterial
blood samples
taken just before
induction of
anaesthesia.
CMV
seronegative
participants
Stroke Derived from the
prospectively
sampled cardiac
surgery database.
Defined as Stroke
with Rankin
grade>1.
CMV reactivation
Yen, 2016[9] Cohort 1998–2012 Taiwan,
National Health
Insurance
Research
Database.
Adults (�15 yr)
newly diagnosed with
HIV, with no history
of stroke or CMV
infection.
CMV end-organ
disease: ICD-9 code
(0.78.5
Cytomegaloviral
disease) and
prescription for an
anti-CMV drug
Participants
without CMV
end-organ
disease
Primary: Any
stroke
Secondary:
ischaemic and
haemorrhagic.
Hospitalisation or
stroke from ICD-9
codes
HHV6 infection
Fullerton, 2017
[58]
Case-
control
2009–2014 United States, Children (aged 28 d
to 18 yrs) with stroke
and stroke-free
trauma controls,
frequency matched
on age.
HHV6 DNA:
MassTag PCR
Participants
without HHV6
DNA
Ischaemic stroke Acute diagnosis of
ischemic stroke
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
VZV infection, serologically defined
Asiki, 2015[59] Case-
control
Unclear Uganda, data
from population
based cohort
study in rural
setting
Adults stroke patients
matched on sex and
age to�4 controls
without stroke. All
participants had
stored serum
samples.
IgG, IgM
antibodies:
quantitative
indirect
chemiluminescent
immunoassays at/
prior to stroke
IgG and IgM
optical
densities
compared in
cases versus
controls
Stroke Prevalent cases
from clinical
symptoms and
deaths due to stroke
by verbal autopsy.
VZV infection, clinically defined (varicella)
Askalan, 2001
[60]
Cohort 1992–1999 Canada, two
hospitals.
Consecutive young
children aged 6 mo to
10 yr with acute (or
unders 3–6 mo
follow-up for) stroke
during the study
period.
Varicella 12 mo
prior to stroke:
parental interview
Patients
without
varicella
Recurrent
cerebral ischaemic
events
TIAs and cerebral
infarctions before
or after the index
AIS: parental
interviews,
radiographic films,
health-record
review
Se´bire, 1999[61] Case-
control
1985–1996 France, referrals
to single
hospital for
stroke treatment
Children with stroke
matched to 4 healthy
children (gender, age
(±4 mo), site of
residence)
Varicella in the 9
mo prior to stroke;
from an obligatory
French health
record
Participants
without
varicella
Ischaemic stroke First idiopathic
arterial ischaemic
stroke: angiograms
and long-term
clinical and
angiographic
follow-up
Thomas, 2014
[62]
SCCS 1990–2011 UK, primary
and secondary
care records
from 4 routinely
collected
databases
Patients (any age)
with first ever stroke/
TIA and chickenpox
during study period.
Varicella: from
Read codes.
Exposed period:
day after varicella
and up to 1 yr after
"Unexposed"
time: all follow-
up time when
individual not
"exposed".
Ischaemic stroke First stroke within
study period;
ascertained from
Read codes.
Vaccination against herpesviruses
Baxter, 2012
[64]
Cohort 2006–2007 United States,
Kaiser
Permanente
Northern
California
(KPNC), health
care system
People (�60 yr)
vaccinated against
HZ in routine
medical care, with
�180 days
continuous KPNC
membership after
vaccination.
HZ vaccination: in
Kaiser
Immunization
Tracking system.
Exposed period:
1–42 days after
vaccination.
Unexposed
period: 91–180
days post
vaccination.
Stroke Evidence of stroke
(hospitalisations
and emergency
department visits)
in 1–42 days
following
vaccination
Kovac, 2018[63] RCT Multi-country,
randomised
placebo-
controlled trial
People(�50 yr)
randomised to
placebo or HZ
subunit vaccine.
Excluded those with
history of zoster,
VZV vaccination, an
immunosuppressive
condition.
HZ subunit
vaccination
Placebo
vaccination.
Stroke Clinical evidence of
stroke (neurological
deficit and change
in consciousness)
and either CT/MRI
scan or no other
sign of a disorder
causing deficits
Tseng, 2012[65] SCCS 2007–2008 United States, 8
managed-care
systems taking
part in Vaccine
Safety Datalink
Project
Patients�50 yr
receiving HZ vaccine
who experienced
stroke. 12 mo
continuous
membership was
required, prior to first
event.
HZ vaccination:
medical records.
Risk windows: 1–14
days, 15–28 days,
29–42 days, 1–42
days from
vaccination.
Same length of
time after a
30-day "wash-
out" period
following the
risk window.
Stroke ICD-9 diagnosis
codes from
inpatients and
emergency
department records,
with no code in the
previous 12 mo
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
Donahue, 2009
[66]
Cohort 1991–2004 United States, 8
managed-care
systems taking
part in Vaccine
Safety Datalink
Project
Immunocompetent
children (11mo to
17yr),�12 mo
continuous
enrolment,�1
encounter with site.
Excluded those with
infantile cerebral
palsy stroke, or
hemiplegia/
hemiparesis at�11
mo of age
Varicella
vaccination:
recorded in
Vaccine Safety
DataLink database.
Exposed period:
12-mo period
following
vaccination.
1) children
without
varicella
vaccination; 2)
exposed
children: all
other person
time not
classified as
exposed.
Ischaemic stroke Primary or
secondary coded
diagnoses in
inpatient settings
using ICD-9 codes
MacDonald,
2018[67]
Cohort 2006–2013 Canada,
administrative
health databases
Children receiving
the varicella
vaccination between
11 months and 23
months of age, and
non-vaccinated
children.
Varicella
vaccination:
recorded in medical
records.
Exposed period:
12-mo period
following
vaccination.
Children
without
varicella
vaccination
Ischaemic stroke ICD-10 codes
recorded in hospital
discharge database
Multiple herpesviruses infections
Al-Ghamdi,
2012[50]
Case-
control
Unclear Saudi Arabia, a
single hospital
setting
Patients with
atherosclerotic
vascular disease,
matched (age, sex) to
15 healthy controls.
Age not specified.
HSV-1 and EBV
IgG antibodies:
ELISA kits. CMV
IgG antibodies:
bioelisa kit.
Participants
with a negative
test result for
exposures
Stroke Not reported
Elkind, 2010
[52]
Cohort 1993–2001 US, community-
based study to
investigate
epidemiology of
stroke.
Adults >39 yr, with
no history of stroke,
residing in household
with a telephone,
with blood samples
available.
CMV, HSV-1 and
HSV-2: Enzyme-
linked
immunoassay used
to measure IgG
antibody titres
against exposures.
Participants
with a negative
test result for
exposures
Stroke Defined using data
from annual
telephone follow-
ups: symptoms and
events consistent
with stroke and
classified by 2
neurologists.
Elkind, 2016
[51]
Case-
control
2010–2014 9 countries,
Vascular Effects
of Infection in
Paediatric
Stroke study
All children (29 days
to 18 yr) presenting
to an included centre
and enroled�3 wk of
stroke, with an
analysable blood
sample.
IgG, IgM antibodies
to HSV-1/2, CMV,
EBV, VZV: blood
samples�3 wk
from stroke using
ELISAs. Clinical
infection, previous
6 mo from parent/
guardian interview.
Participants
without
evidence of
infection.
Ischaemic stroke Arterial ischaemic
stroke: from clinical
and imaging data by
a trained specialist.
Kis, 2007[53] Case-
control
2003 Hungary,
patients
hospitalised in
2003
Cases (<65 yr)
admitted <72 hr after
stroke. Controls (<76
yr) admitted for pain,
without ischaemic
stroke. Patients with
history of MI, atrial
fibrillation, valvular
or myocardial heart
disease excluded.
CMV DNA: PCR
IgG, IgA, IgM
antibodies to HSV-
1, CMV, EBV and
HHV-6: ELISA,
blood samples
taken�1 wk from
stroke.
Participants
without
evidence of
infection.
Ischaemic stroke First
noncardiogenic
ischaemic stroke:
from clinical
examinations and
imaging techniques.
(Continued)
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Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
Li, 2005[54] Case-
control
2001–2002 China,
department of
neurology in a
single hospital
Cases (age
unspecified) of stroke
in progression.
Excluded those with
embolism and
reversible ischaemic
neurological deficit,
cerebral
haemorrhage,
haemorrhagic
infarction, >5 yr
history of severe
disease. Controls
were patients with
non-cerebrovascular
disease.
CMV, HSV-1 and
HSV-2 IgM: dot
immunogold
labelling staining
performed after
stroke diagnosis
(date unknown).
Patients
without
herpesvirus
IgM in blood
Stroke in
progression
Brain damage
caused by an
obstruction to the
blood supply not
preventable with
convention
treatment (e.g.
urokinase for
injection) within 72
hours from stroke
onset. Confirmed
with CT and/or
MRI.
Ozturk, 2013
[55]
Case-
control
Unclear Turkey,
department of
neurology in a
single hospital
Cases (>40 yrs) were
patients presenting
with stroke <24
hours of onset
matched (age) to
controls without
ischaemic stroke or
TIA. Patients with
TIA, subarachnoidal
hemorrhage, cerebral
venous sinus
occlusion with
ischemic stroke due
to head trauma were
excluded.
CMV, EBV IgG:
blood samples.
CMV tested using
ELISA and EBV
tested using Viral
capsid antigen
Patients
without
herpesvirus
IgG in blood
Ischaemic stroke Sudden focal or
global cerebral
impairment and at
least one acute
lesion. Computed
tomography (CT)
and magnetic
resonance imaging
(MRI) were
performed in all
patients during the
first 24 hours
Ridker, 1998
[56]
Case-
control
Unclear US, Physicians
Health Study
(RCT among
male doctors
with no history
of MI, stroke or
cancer).
Cases (age
unspecified) were
patients developing
stroke/MI, matched
(age, smoking,
follow-up) to controls
without MI or stroke.
Participants with
baseline blood
samples included
(14916/22071 [68%]).
CMV, HSV1/2
infection: plasma
assayed using
ELISA for presence
or absence of IgG
antibodies directed
against HSV and
CMV.
Seropositivity
was compared
in cases versus
controls
Thromboembolic
stroke
Hospital records
and autopsy reports
were used to
confirm each
diagnosis according
to prespecified
criteria
Sealy-Jefferson,
2013[57]
Cohort 1998–2008 US, cohort of
Mexican
Americans from
the Sacramento
Area Latino
Study on Aging,
community-
dwelling
Participants from the
cohort (60–101 yr at
baseline) without a
history of stroke at
baseline.
CMV, HSV-1 and
VZV IgG
antibodies: solid-
phase ELISA.
Measured at
baseline and follow-
up visits
Seronegative to
herpesviruses
of interest.
Incident stroke Self-reported:
determined at
follow-up visits and
semi-annual
telephone calls.
Fatal strokes
identified from
death certificates
using the ICD-10
code 164.
(Continued)
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Zoster was associated with a 1.5-fold increased stroke risk four weeks following onset (sum-
mary estimate: 1.55, 95%CI 1.46–1.65), with the risk decreasing to baseline after around one
year (Fig 2). Removing three studies at high-risk of bias eliminated statistical heterogeneity in
cohort studies with “Over 1 year follow-up” (I2<0.01%, see S1 Table). There were no SCCS at
high-risk of bias. There was moderate quality evidence of an increased risk of stroke following
zoster, with evidence upgraded due to some strong associations and a clear dose-response gra-
dient over time.
Two studies reported an increased risk of TIA following zoster. The first showed over 50%
increased risk (IRR1.56, 95%CI:1.13–2.15) over a maximum of 10 years follow-up[34] and the
second around 15% increased risk (HR1.15, 95%CI:1.09–1.21) during a median follow-up of
6.3 years.[22] Only a single SCCS study assessed the effect of zoster vaccination on stroke risk,
using Medicare claims data; this study found no evidence that zoster vaccination attenuated
stroke risk, however only 3% of study participants were vaccinated which limited the study’s
ability to detect an effect.[35]
Results can be found in S1, S2, S3, S4 and S5 Figs. Ophthalmic zoster was associated with
increased risk of stroke, of a larger magnitude than zoster at any site. The pooled estimate for
stroke up to 4 weeks following ophthalmic zoster in SCCSs was 1.77 (95%CI:1.53–2.05), com-
pared to 1.55 (95%CI:1.46–1.65) following any zoster (S1 Fig). Another study found the ele-
vated risk of stroke among rheumatoid arthritis patients experiencing zoster was greatest in
those patients with a neurological complication.[33] Antiviral agents appeared to attenuate
stroke risk in two out of three studies, though the confidence intervals for effect estimates for
zoster patients given and not given antivirals overlapped (S2 Fig). In one SCCS study, in the
first four weeks following zoster there appeared to be no evidence of an increased risk of stroke
among those given antivirals (IRR1.23, 95%CI:0.89–1.70), whilst for those not given antivirals
there was an association (IRR2.14, 95%CI:1.62–2.83). A larger effect of zoster on stroke risk
was seen in people aged below 40 years (S3 Fig); there was no difference of zoster on stroke
risk by gender (S4 Fig); and little difference in stroke risk by stroke type (ischaemic versus hae-
morrhagic), except in one cohort study from Taiwan[24] where the magnitude of association
was greater for haemorrhagic stroke (S5 Fig).
Table 1. (Continued)
Author, yr Design Study period Setting Study population at
recruitment
Exposure definition
and ascertainment
Comparator
definition and
ascertainment
Outcome type Outcome definition
and ascertainment
Yen, 2017[30] Cohort 2000–2012 Taiwan,
National Health
Insurance
Research
Database.
Patients (�15 yr)
with new HIV
diagnosis. Patients
who received a stroke
diagnosis were
excluded.
HZ and CMV
disease after HIV
diagnosis: ICD-9
codes from an
inpatient setting or
in�3 outpatient
visits.
Participants
without
diagnosis codes
for HZ or
CMV.
Stroke Patients
hospitalised for
stroke, identified
through ICD-9
codes
Abbreviations: RCT = randomised controlled trial, SCCS = self-controlled case series, RR = risk (or rate) ratio, CI = confidence interval, transient ischaemic
attack = TIA, HZ = herpes zoster, HZO = herpes zoster opthalmicus, ESRD = End-stage renal disease, CT = computerised tomography, MRI = magnetic resonance
imaging, IBD = inflammatory bowel disease, SLE = systemic lupus erythematosus, MS = multiple sclerosis, RA = rheumatoid arthritis, HMO = health maintenance
organization, GPRD = General Practice Research Database, THIN = The Health Improvement Network, CVD = cardiovascular disease, MEIA = micro-particle enzyme
immunoassay technique, CMIA = chemiluminescent microparticle immunoassay, CAD = coronary artery disease, MI = myocardial infarction, ACE = angiotensin-
converting–enzyme, IU = International Units, yr = year, mo = mo, wk = wk, hr = hour
�Or Odds Ratio (OR) if specified.
https://doi.org/10.1371/journal.pone.0206163.t001
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Table 2. Study results.
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
VZV reactivation—
herpes zoster
Breuer, 2014 Cohort Exposed = 106,601
Unexposed = 213,202
Follow-up (median): 6.3 yr
Stroke
Exposed = 5,252 (2.46%)
Unexposed = 2,727 (2.56%)
Cox proportional
hazard models
Stroke: HR 1.02 (95% CI
0.98–1.07)
Matching variables (age, sex),
obesity, smoking, history of
cholesterol, hypertension,
diabetes, IHD, atrial fibrillation,
intermittent arterial claudication,
carotid stenosis, heart disease
Calabrese, 2017 Cohort N = 43,527
Follow-up: up to 7 yr (total
64,528.2 pyr)
N = 680, 1.6% Generalized linear
models
0-90d: IRR 1.36 (1.10–1.68)
91-365d: IRR 1.18 (1.00–
1.40)
Baseline: 366-730days
Age, sex, race, diabetes mellitus,
hypertension, atrial fibrillation,
TIA, glucocorticoids.
Hosamirudsari,
2018
Case-
control
Cases = 105
Controls = 105
Cases: 24/105 (22.9%)
Controls: 5/105 (4.8%)
Logistic regression OR, 5.84 (95% CI, 1.98-
8.23)
Age, sex, and hypertension.
Kang, 2009 Cohort Exposed = 7760
Unexposed = 23,280
Follow-up: up to 1 year
Exposed = 133, 1.7%
Unexposed = 306, 1.3%
Cox proportional
hazard models
Risk of stroke during the
1-yr follow-up period: HR
1.31 (95% CI 1.06–1.60)
Age, sex, income, urbanization,
geographical location,
hypertension, diabetes, renal
disease, CHD, hyperlipidemia,
atrial fibrillation, heart failure,
heart valve/myocardium disease,
and/or carotid/peripheral vascular
disease
Kim, 2017 Cohort Exposed = 23,213
Unexposed = 23,213
Follow-up: up to 10 yr
Not reported Not reported HR 1.35 (95% CI 1.18–
1.54)
Age, sex, BMI, smoking, drinking,
exercise, economic class,
hypertension, diabetes,
dyslipidemia, angina, TIA, heart
failure, atrial fibrillation, heart
disease, renal disease, carotid
stenosis, peripheral vascular
disease, liver disease, rheumatoid
disease, inflammatory bowel
disease, malignancy,
transplantation, HIV, depression.
Kwon, 2016 Cohort Exposed = 77 781
Unexposed = 695755
Follow-up: up to 11 yr (total
7,770,699 years)
Crude incidence rate:
9.8/1000 py
Time-updated Cox
models
18–30 yrs: HR 1.52, 95% CI
1.26–1.83
30–40 yrs: HR 1.34, 95% CI
1.19–1.51
40–50 yrs: HR 1.19, 95% CI
1.12–1.29
50–60 yrs: HR 1.12, 95% CI
1.06–1.19
60–70 yrs: HR 1.14, 95% CI
1.08–1.20
>70 yrs: HR 1.14, 95% CI
1.06–1.23
Age, gender, hypertension,
hyperlipidaemia, IHD, diabetes,
heart failure, peripheral vascular
disease, atrial fibrillation or atrial
flutter, chronic renal disease,
valvular heart disease (time-
updated)
Langan, 2014 SCCS N = 6584
Follow-up (median): 12.5 yr (IQR,
8.7–17.1).
wk 1–4: n = 90
wk 5–12: n = 149
wk 13–26: n = 215
wk 27–52: n = 303
Conditional
Poisson regression
wk 1–4: IR 1.63 (1.32–2.02)
wk 5–12: IR 1.42 (1.21–
1.68)
wk 13–26: IR 1.23 (1.07–
1.42)
wk 27–52: IR 0.99 (0.88–
1.12)
Age and time-invariant
confounders
Liao, 2017 Cohort HZ patients = 2744
Non HZ patients = 5475
Exposed = 116, 4.2%
Unexposed = 186, 3.4%
Cox proportional
hazard models
0-90d: HR 2.30 (95%CI
1.13–4.69)
91-365d: HR 1.05 (95%CI
0.58–1.90)
366-730d: HR 1.16 (95%CI
0.70–1.92)
>730d: HR 1.18 (95%CI
0.86–1.64)
Age, sex, atrial fibrillation, CKD,
COPD, diabetes mellitus,
dyslipidemia, and hypertension
Lin, 2010 Cohort Exposed = 658
Unexposed = 1974
Follow-up: up to 1 yr
Exposed = 53, 8.1%
Unexposed = 33, 1.7%
Cox proportional
hazard
regressions
HR 4.52 (95% CI 2.45–
8.33)
Age, gender, hypertension,
diabetes, hyperlipidemia, CHD,
chronic rheumatic heart disease,
other forms of heart disease, and
medication habits
(Continued)
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Table 2. (Continued)
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
Minassian, 2015 SCCS N = 42,954
Follow-up (median): 5 yr (IQR:
4–5 yr)
Baseline: n = 32179
wk 1: n = 499
wk 2–4: n = 967
wk 5–12: n = 1841
wk 13–26: n = 2588
wk 27–52: n = 3981
Conditional
Poisson regression
wk 1: IR 2.37, 95% CI
2.17–2.59
wk 2–4: IR 1.55, 95% CI
1.46–1.66
wk 5–12: IR 1.17, 95% CI
1.11–1.22
wk 13–26: IR 1.03, 95% CI
0.99–1.07
wk 27–52: IR 1.00, 95% CI
0.96–1.03
Age in 2-yr age bands and time-
invariant confounders
Patterson, 2018 Cohort Exposed = 23,339
Unexposed = 46,378
Follow-up: up to 10 yr
Exposed = 141, 6.0%
Unexposed = 262, 5.6%
Multivariate
Poisson models
IRR 1.40 (95%CI 0.93–
2.11)
Sociodemographic and clinical
factors, including smoking status
and BMI
Schink, 2016 SCCS N = 6,035
Followup time (mean): 5.6 yr 3 mo following zoster: N = 352
Log-linear Poisson
model
<2 wk: 1.30 (1.00–1.68)
wk 3–4: IRR 1.52 (1.20–
1.91)
mo 2–3: IRR 1.24 (1.08–
1.42)
mo 4–6: IRR 1.09 (0.97–
1.24)
mo 7–12: IRR 0.96 (0.87–
1.06)
Age
Sreenivasan,
2013
Cohort N = 4,503,054
Exposed: 117926
Follow-up: up to 14 years
Overall:
N = 230341, 5.0%.
Exposed: 4876/117926, 4.1%
Poisson regression < 14 days since HZ: IRR
2.27 (95%CI 1.83–2.82)
14 days-1 yr: IRR 1.17
(95%CI 1.09–1.24)
> 1 yr: IRR 1.05 (95%CI
1.02–1.09)
Age, sex, calendar period.
Sundstro¨m, 2015 Cohort General population = 4,707,885
Exposed = 13296
All followed for 1-yr.
Exposed = 111
General population = unknown
Poisson regression IRR 1.34 (95% CI 1.12–
1.62)
Age and sex.
Tseng, 2011 Cohort Not reported
Follow-up: up to 4 years
Exposed = 227
Unexposed = 224
Not reported HR 1.11 (95% CI 0.92 to
1.33)
Matching factors (age and sex),
race, heart diseases, diabetes, lung,
kidney, liver disease,
hypertension, dementia
Yawn, 2016 Cohort Exposed = 4478Unexposed =
16,800Follow-up (mean): 7.1 yr
(range 0–28.6 yr)
EverExposed = 562, 12.6%
Unexposed = 1844, 11.0%
Logistic regression OR (95% CI):3 mo: 1.53
(1.01–2.33)6 mo: 1.28
(0.91–1.80)1 yr: 1.04 (0.79–
1.36)3 yr: 1.02 (0.86–1.22)
3 mo: Age, vasculopathy,
arrhythmias.6 mo: Age,
vasculopathy, hypertension.1 yr:
Age, vasculopathy, hypertension,
CAD, dyslipidemia.3 yr: Age,
gender, hypertension, CAD,
dyslipidemia, depression,
vasculopathy.
CMV infection
Coles, 2003 Case-
cohort
Stroke cases = 119
Random sub-cohort = 451
Follow-up time: up to 3 years
CMV IgG: Stroke cases: 84.9%;
Random sub-cohort: 85.4%
High level CMV IgG: Stroke cases:
40.3%; Random sub-cohort: 38.1%
Cox proportional
hazards regression
CMV IgG: RR 0.93 (95%
CI 0.46, 1.89)
CMV IgG high titre: RR
0.78 (95% CI 0.49, 1.23)
Age, gender, BMI, cholesterol,
triglycerides, diabetes,
haemoglobin, treatment for
hypertension, systolic blood
pressure and smoking.
Fagerberg, 1999 Cohort N = 152
Follow-up (median): 6.5 yr (range
0.2–7.5)
Not reported Poisson regression Relative Risk of High
Titres of Antibodies to
CMV for Stroke: RR 1.04
(95% CI 0.13–8.51)
Smoking, presence of previous
cardiovascular disease, group
allocation in the underlying
multiple risk factor intervention
study (multifactorial risk factor
intervention or usual care)
Gonza´lez-
Quijada, 2015
Case-
control
Cases = 111
Controls = 523
Cases: Seropositive CMV = 98,
95.1%; High-titre IgG
antibodies = 37, 35.0%
Controls: Seropositive CMV = 455,
92.9%; High-titre IgG
antibodies = 109, 22.2%
Logistic regression High-titre IgG antibodies
(top quartile) against CMV
(OR 2.1, 95% CI 1.3 to 3.5)
Adjusted for sex, age >81 yr,
hypertension, dyslipidaemia,
smoking habits, diabetes,
cardioembolic focus, other
vascular diseases, white blood
cells, and C-reactive protein.
(Continued)
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Table 2. (Continued)
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
Huang, 2012 Case-
control
Cases = 200
Controls = 200
CMV DNA
Cases (stroke) = 110, 55%
Controls = 47, 23.5%
Logistic regression Odds of stroke associated
with CMV DNA
Any stroke: OR 3.98 (95%
CI 2.50–6.32)
Age, sex, BMI, hypertension and
smoking
Kenina, 2010 Case-
control
Cases = 102
Controls = 48
CMV seropositivity
Cases = 95/102, 93%;
Controls = 45/48, 94%
Mean CMV IgG antibody levels
(IU/ml)
Cases: 6.43 ± 2.6; Controls:
5.83 ± 2.7
None OR for CMV
seropositivity: OR 0.90
(95% CI 0.22–3.66)
[calculated by review
authors]
None
Oliveras, 2003 Cohort N = 403
Time from RT until stroke = 49.3
mo (SD = 25.6 mo)
Total: N = 19 (7.97%) at 10 yr
follow-up. Denominator inferred
to be 238
Exposed: 0/16, 0%
Unexposed: 19/387, 4.9%
Chi-squared test RR 0.60 (95% CI 0.03–
10.41)1
[calculated by review
authors]
None
Shen, 2011 Case-
control
Cases = 81
Controls = 72
Cases: 40/81 (49.4%)
Controls: 13/72 (17.8%)
Chi-squared test OR 4.51 (95% CI: 2.16–
9.40)
None
Smieja, 2003 Cohort N = 3168
Follow-up (mean) = 4.5 yr
Overall: 107/3164 (3.4%) Cox proportional
hazards
HR 0.93 (95% CI 0.61,
1.42)
Age, sex, smoking status, ramipril
randomization, diabetes mellitus,
hypertension, and history of
hypercholesterolemia
Tarnacka, 2002 Case-
control
Cases: n = 56
"Old" controls: n = 53
"Young" controls: n = 57
IC Containing Anti-CMV
Antibodies
Cases: 41/55 (74.5%)
Old controls: 11/42 (26.2%)
Young controls: 23/57 (40.4%)
Not reported Increased levels of serum
CMV-specific IC were
connected with increased
risk of stroke incidence
(odds ratio, 7.60; 95% CI,
3.21 to 17.96)3.
None reported
Yi, 2008 Case-
control
Cases = 35
Controls = 20
CMV IE genes/proteins
Cases: 21/35 (60.0%), Controls: 6/
20 (30.0%)
CMV L genes/proteins
Cases: 7/35 (20.0%), Controls: 4/20
(20.0%)
Chi-squared tests CMV IE genes/protein:
3.50 (1.08–11.29)
CMV L genes/protein: 1.00
(0.25–3.95)
[calculated by review
authors—matching not
accounted for]
No adjustments made—matched
on age and sex
Zheng, 2016 Case-
control
Controls = 300
Cases = 300
Follow-up (median): 8.4 yr
Proportion of patients with CMV
DNA
Cases: 38/300 (12.7%)
Controls: 17/300 (5.7%)
Conditional
logistic regression
OR 1.46 (95% CI, 1.00–
2.14)
Matching factors (age, gender,
follow-up, stage of hypertension),
pulse rate, BMI, LDL-C, HDL-C,
triglycerides, fasting glucose,
smoking, drinking,
antihypertensives, statins,
antiplatelet agents, and
anticoagulants
Ziemann, 2016 Cohort N = 983
Follow-up: unclear
CMV seropositive: n = 8/618 (1%)
CMV seronegative: n = 6/365 (2%)
Chi-square test Risk ratio: 0.79 (95% CI
0.28–2.25)
[calculated by review
authors]
None reported
CMV reactivation
Yen, 2016 Cohort Total: N = 22,581Exposed = 439,
follow-up time 6.1 yr (SD = 3.8)
Unexposed = 22,142, follow-up
time 4.8 yr (SD = 3.7)
Exposed: 17/439 (3.2%)Unexposed:
211/22,142 (0.7%)
Cox proportional-
hazards model
HR, 3.07; 95% CI, 1.70 to
5.55
Age, sex, diabetes, CKD,
hypertension, CHD, cancer,
dyslipidaemia, tuberculosis
infection, disseminated
Mycobacterium avium complex
infection, pneumonia, meningitis,
Penicillium marneffei infection,
toxoplasma encephalitis,
candidiasis, HZ and HAART.
HHV6 infection
Fullerton, 2017 Case-
control
Cases = 161
Controls = 34
Cases: 2/161 (1.2%)
Controls: 0/34 (0%)
Not reported OR 1.07 (95% CI 0.05–
22.7)1
[calculated by review
authors]
No adjustments made—matched
on age
(Continued)
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Table 2. (Continued)
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
VZV infection, serologically defined
Asiki, 2015 Case-
control
Cases = 31
Controls = 132
All participants had detectable IgG
and IgM antibodies against VZV
Mann–Whitney
two-sample test
Median VZV IgG (IQR) at
index date
Cases: 2.06 (1.45–2.42)
Controls: 1.91 (1.52–2.26);
P value: 0.47
Median VZV IgM (IQR) at
index date
Cases: 0.32 (0.19–0.43)
Controls: 0.29 (0.20–0.50);
P value: 0.69
No adjustments made—matched
on age and sex
VZV infection, clinically defined (varicella)
Askalan, 2001 Cohort
Exposed = 22
Unexposed = 48
Follow-up: up to 12 months
Exposed: 10/22 (45%)
Unexposed: 8/48 (17%)
Not reported OR 4.1 (95% CI 1.3–12.9)
[calculated by review
authors]
No adjustments made
Se´bire, 1999 Case-
control
Cases = 11
Controls = 44
Cases: 7/11 (64%)
Controls: 4/44 (9%)
Fisher’s exact test OR: 17.5 (95% CI 3.53–
86.83)
[Calculated by review
authors]
No adjustments made—matched
on age, sex and site of residence
Thomas, 2014 SCCS
Children = 60, median follow-up
6.6 yr (IQR 4.7–11.7)
Adults = 500, median follow-up
14.2 yr (IQR 9.9–18.8)
Children = 49
0–6 mo: 12; 7–12 mo: 6;
Unexposed period: 31
Adults = 241
0–6 mo: 20; 7–12 mo: 11;
Unexposed period: 210
Conditional
Poisson regression
for individual
database, meta-
analysis for
combined
databases
Children (fixed effects
meta-analysis)
0-6mo: IR 4.07 (95% CI
1.96–8.45)
7–12 mo: IR 2.37 (95% CI
0.93–6.06)
Adults (random effects
meta-analysis)
0–6 mo: IR 2.13 (95% CI
1.05–4.36)
7–12 mo: IR 1.23 (95% CI
0.66–2.30)
Age (in 5-yr bands).
Vaccination against herpesviruses
Baxter, 2012 Cohort N = 29,010
Cohort followed for 180d
N = 193, with 38 confirmed after
case review by specialists (risk
period of the stroke unknown)
Exact conditional
method
RR = 0.91; 95% CI: 0.43–
1.81
None (design accounts for within
person confounding)
Kovac, 2018 RCT Vaccinated group: 13,881
Placebo group: 14,035
Follow-up (mean): 3.9 ± 0.7 years
Vaccinated group: 0(0%)
Placebo group: 0 (0%)
None OR: 1.01 (95% CI 0.02–
51.0)1
[Calculated by review
authors]
None (randomised design
accounts for confounders)
Tseng, 2012 SCCS Days 1–14: n = 167
Days 15–28: n = 147
Days 29–42: n = 169
Days 1–42: n = 468
Follow-up: 42 days
No. of cases in risk window/control
window.
Days 1–14: 81/86
Days 15–28: 74/73
Days 29–42: 83/86
Days 1–42: 233/235
Conditional
Poisson regression Days 1–14: RR 0.94 (95%
CI 0.70–1.28)
Days 15–28: RR 1.03 (95%
CI 0.74–1.42)
Days 29–42: RR 0.97 (95%
CI 0.71–1.30)
Days 1–42: RR 0.99 (95%
CI 0.83–1.19)
None (design accounts for within
person confounding)
Donahue, 2009 Cohort N = 3240473
Vaccinated: 1,142,920
Unvaccinated: 2,097,553
Follow-up: up to 13 yr (total py
17.2 million)
Vaccinated: n = 39 (0.003%) (8
occurred in 12 mo risk period
following vaccination)
Unvaccinated: n = 164 (0.008%)
Cox regression
adjHR (95% CI) after
vaccination
0 to <1 mo: 1.1 (0.1–9.2)
1 to <3 mo: 0.7 (0.1–5.7)
3 to <6 mo: 1.3 (0.3–5.6)
6 to <9 mo: 1.3 (0.4–4.9)
9 to <12 mon: 0.4 (0.0–
3.2)
Gender, calendar time,
geographical site, cardiac disease,
rheumatic heart disease and
endocarditis, CVD, sickle cell
disease, conditions predisposing
to vasculopathy, coagulation
abnormalities, and diseases
leading to a hypercoagulable state.
MacDonald,
2018
Cohort
Vaccinated: 325,729
Unvaccinated: 43,263
Follow-up: 1 yr
Vaccinated group: 25 (0.01%)
Unvaccinated group: 6 (0.01%)
Cox proportional
hazards model
HR 1.6 (95% CI 0.7–3.7) Moyamoya disease, Sickle cell
disease, Congenital heart disease,
Meningitis, Severe sepsis,
Intracranial injury, Varicella
infection, AIS history before 11
months of age.
(Continued)
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Table 2. (Continued)
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
Multiple herpesviruses
infections
Al-Ghamdi,
2012
Case-
control
Cases = 20
Controls = 15
HSV-1—Cases: n = 20, 100%;
controls n = 14, 93.9%
CMV—Cases: n = 9,45%; controls
n = 3, 20%.
EBV—Cases: n = 18, 90%; controls
n = 14, 93.3%.
Chi-squared test HSV-1: OR 2.86 (95% CI
0.09–91.16)1
CMV: OR 3.27 (95% CI
0.70–15.29)
EBV: OR 0.64 (95% CI
0.05–7.83)
[calculated by review
author]
No adjustments made—matched
on age and sex
Elkind, 2010 Cohort N = 1625, Median follow-up 7.6
yr (IQR: 6.4–9.0)
CMV = 1388 (85.4%)
HSV-1 = 1402 (86.3%)
HSV-2 = 928 (57.1%)
Overall: 67 strokes (56 ischaemic) Cox proportional
hazards models
CMV IgG: HR 2.19 (95%
CI 0.84–5.70)
HSV-1 IgG: HR 1.35 (95%
CI 0.59–3.07)
HSV-2 IgG: HR 1.59 (95%
CI 0.91–2.76)
Age, sex, ethnicity, education,
systolic blood pressure, cholesterol
level, alcohol use, smoking status,
waist circumference, physical
activity, and CAD
Elkind, 2016 Case-
control
Cases = 326Controls = 115 Past infection:HSV-1/2: Cases: 53,
16.3%; controls 24, 20.9% CMV:
Cases: 95, 29.1%; controls 42,
36.5% EBV: Cases: 176, 54.0%;
controls 58, 50.4% VZV: Cases:
182, 55.8%; controls 68, 59.1%
Acute Infection:HSV-1/2: Cases:
80, 24.5%; controls 19, 16.5%
CMV: Cases: 18, 5.5%; controls 2,
1.7% EBV: Cases: 4, 1.2%; controls
1, 0.9% VZV: Cases: 37, 11.3%;
controls 3, 2.6%
Logistic regression Past infection:HSV-1/2:
OR 0.78 (95% CI 0.45–
1.35)CMV: OR 0.74 (95%
CI 0.47–1.17)EBV: OR 1.26
(95% CI 0.82–1.95)VZV:
OR 0.93 (95% CI 0.60–
1.44)Acute Infection:HSV-
1/2: OR 1.68 (95% CI 0.98–
3.00)CMV: OR 2.85 (95%
CI 0.79–18.2)EBV: OR 1.44
(95% CI 0.21–28.4)VZV:
OR 4.43 (95% CI 1.55–
18.7)
Age.�Age, Race, Residence (urban,
rural, suburban), country income
(low/middle or high income)
Kis, 2007 Case-
control
Cases = 59
Controls = 52
CMV DNA—Cases: n = 1, 1.7%;
Controls: n = 0, 0%
CMV IgM—Cases: n = 0, 0%;
Controls: n = 0, 0%
CMV IgG—Cases: n = 26, 44.1%;
Controls: 11, 21.2%
HSV-1 IgA—Cases: n = 24, 40.7%;
Controls: n = 8, 15.7%
HSV-1 IgG—Cases: n = 23, 39.0%;
Controls: n = 14, 27.4%
EBV IgG—Cases: n = 22, 37.3%;
Controls: n = 15, 28.8%
HHV-6 IgG—Cases: n = 19, 32.2%;
Controls; n = 18, 34.6%
Logistic regression Highest tertile v. lower two
tertiles
CMV IgG†: OR 4.95 (95%
CI 1.38–17.80)
HSV-1 IgA‡: OR 3.69 (95%
CI 1.47–9.21)
[below calculated by
review authors—
unadjusted]
CMV DNA: OR 2.69 (95%
CI 0.11–67.53)1
CMV IgM: OR 0.88 (95%
CI 0.01–45.2)1
HSV1 IgG: OR 1.73 (95%
CI 0.77–3.88)
EBV IgG: OR 1.46 (95% CI
0.66–3.26)
HHV-6 IgG: OR 0.90
(0.41–1.98)
Age, gender, smoking, alcohol,
lipid, hypertension, sedimentation
rate
Li, 2005 Case-
control
Cases = 47
Controls = 193
CMV: Cases: 20/47 (43%2);
Controls: 20/193 (10%)
HSV-1: Cases: 6/47 (13%2);
Controls: 7/193 (4%)
HSV-2: Cases: 7/47 (15%2);
Controls: 22/193 (11%)
Chi-squared test CMV: OR 6.41 (95% CI
3.05–13.44)
HSV-1: OR 3.89 (95% CI
1.24–12.18)
HSV-2: OR 1.36 (95% CI
0.54–3.40)
[calculated by review
authors]
None
Ozturk, 2013 Case-
control
Cases = 72
Controls = 60
CMV: Cases: n = 71/72 (98.6%);
Controls: n = 58/60 (96.7%)
EBV: Cases: n = 41/72 (56.9%);
Controls: n = 29/60 (48.3%)
Logistic regression CMV: OR 2.45 (95% CI
0.22–27.68)
EBV: OR 1.41 (95% CI
0.71–2.81)
[calculated by review
authors]
No adjustments made—matched
on age
(Continued)
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CMV infection, defined largely using laboratory criteria, was investigated in 22 studies[9,
30, 38–57] using data from a variety of settings including electronic healthcare records, survey
data and trial data (Table 1).
Among studies assessing CMV infection (past or recent), 19/22 studies had a least one
domain at high-risk of bias, including: confounding (ten studies had no age-adjustment) and
reverse causation (10 studies recorded CMV following stroke).
14 studies investigated past CMV infection and stroke risk (Fig 3); IgG seropositivity and/or
high titre IgG antibodies were investigated. IgG seropositivity was not associated with stroke
when combining six case-control studies (summary estimate:1.40, 95%CI:0.67–2.96; I2 = 78.8%)
nor in cohort studies (summary estimate:1.01,95%CI:0.73–1.39, I2<0.001%). While having a high
IgG titre compared to a low titre was associated with stroke when combining two case-control
studies (summary estimate:2.61,95%CI:1.26–5.43, I2 = 33.4%) it was not associated with stroke
when pooling three cohort studies (summary estimate:0.80,95%CI:0.62–1.05, I2<0.001%).
Recent CMV infection or reactivation was investigated in 11 case-control studies (Fig 3),
using a variety of exposure definitions. In a meta-analysis of two studies, IgM seropositivity
was associated with increased stroke risk (summary estimate:5.53,95%CI:2.83–10.81,
I2<0.001%). When pooling three studies, CMV DNA was also associated with increased stroke
risk (summary estimate:2.34,95%CI:0.95–5.74, I2 = 81.4%). In two of three studies among
immunosuppressed patients, clinical CMV reactivation was associated with around 3-fold
increased risk of stroke.
There was very low-quality evidence suggesting there is no association between past infec-
tion with CMV and stroke and an increased risk of stroke following recent infection/reactiva-
tion with CMV.
Table 2. (Continued)
First author,
publication yr
Design Population size (N), follow-up
time (yr)
Subjects with outcome [or
exposure for case-control studies]
(N, %)
Statistical analysis
method used
Main reported results Adjusted for
Ridker, 1998 Case-
control
Cases = 643 (only 271 were stroke
patients)
Controls = 643
HSV-1/2: Stroke cases: n = 271
(73.6%); Controls: n = 643 (69.4%)
CMV: Stroke cases: n = 271
(65.3%); Controls: n = 643 (70.2%)
Conditional
logistic regression
HSV-1/2: RR 1.0 (95% CI
0.7–1.5)
CMV: RR 0.67 (95% CI
0.4–1.0)
Matching factors (age, smoking,
follow-up), treatment assignment,
BMI, hypertension,
hypercholesterolemia, diabetes,
and a family history of premature
atherosclerosis.
Sealy-Jefferson,
2013
Cohort Total N = 1621.
CMV: 979 (60.4%)
VZV: 299 (18.4%)
HSV-1: 1014 (62.6%)
Folow-up: up to 10 yr
CMV: Exposed: 97 (9.9%);
Unexposed: 67 (10.4%)
VZV: Exposed: 36 (12.0%);
Unexposed: 128 (9.7%)
HSV-1: Exposed: 94 (9.3%);
Unexposed: 70 (11.5%)
Discrete-time
logistic regression
IgG in the 75th versus 25th
percentile
CMV: OR 0.81 (95% CI
0.58, 1.12)
VZV: OR 0.93 (95% CI
0.71, 1.20)
HSV-1: OR 0.77 (95% CI
0.56, 1.07)
Hypertension, diabetes,
hyperlipidaemia, smoking, atrial
fibrillation, BMI, coronary heart
disease and/or peripheral artery
disease, education, age and
gender.
Yen, 2017 Cohort
HIV patients: N = 21,375. Mean
follow-up time 4.65 yr (SD 3.36).
CMV infection: 10/311 (3.2%); No
CMV infection 242/21064 (1.2%)
HZ: 238/20020 (1.2%); No HZ: 14/
1355 (1.0%)
Cox regression
model
CMV infection: HR 2.71
(95% CI 1.34 to 5.49)
HZ: HR 0.80 (95% CI 0.46
to 1.40)
Age, sex, diabetes, chronic kidney
disease, hypertension, coronary
heart disease, cancer,
dyslipidemia, and systemic lupus
erythematosus and HAART.
Abbreviations: RCT = randomised controlled trial, SCCS = self-controlled case series, RR = risk (or rate) ratio, CI = confidence interval, transient ischaemic
attack = TIA, COPD = chronic obstructive pulmonary disorder, CKD = chronic kidney disease, HZ = herpes zoster, HZO = herpes zoster opthalmicus, ESRD = End-
stage renal disease, CT = computerised tomography, MRI = magnetic resonance imaging, yr = year, mo = mo, wk = wk, pyr = person years
1Due to zero events in specific cells, 0.5 was added to all cells to calculate an effect estimate.
2Percentages in paper recalculated due to assumed rounding error
3Unclear which controls were used in the calculation of the effect estimate
https://doi.org/10.1371/journal.pone.0206163.t002
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Table 3. Risk of bias summary showing judgements about each risk of bias domain.
First author, publication yr Confounding Selection of participants Misclassification of variables Bias due to missing data Reverse Causation
VZV reactivation—Herpes zoster
Breuer, 2014 • • • • •
Calabrese, 2017 ▪ • • • •
Hosamirudsari, 2018 ▪ ^ ^ • •
Kang, 2009 • • • • •
Kim, 2017 ^ • • • •
Kwon, 2016 ^ • • • •
Langan, 2014 • • • • •
Liao, 2017 ▪ • • • •
Lin, 2010 • • • • •
Minassian, 2015 • • • • •
Patterson, 2018 ^ • • • •
Schink, 2016 • • • • •
Sreenivasan, 2013 ▪ • • • •
Sundstro¨m, 2015 ^ � • • •
Tseng, 2011 � • • • •
Yawn, 2016 • • • • •
CMV infection
Coles, 2003 ▪ • • • •
Fagerberg, 1999 ^ ▪ • • •
Gonza´lez-Quijada, 2015 ▪ ^ • • ^
Huang, 2012 • ▪ • • ^
Kenina, 2010 ^ ^ • • ^
Oliveras, 2003 ^ � • • •
Shen, 2011 ^ ^ • • ^
Smieja, 2003 ▪ • • � •
Tarnacka, 2002 ^ ^ • • ^
Yi, 2008 ^ ^ • • ^
Zheng, 2016 • • • • •
Ziemann, 2016 ^ ▪ ▪ • •
CMV reactivation
Yen, 2016 • • • • •
HHV 6 infection
Fullerton, 2017 ^ ▪ • • ^
VZV infection, serologically defined
Asiki, 2015 ▪ ^ ▪ • •
VZV infection, clinically defined (varicella)
Askalan, 2001 ^ ^ ^ • •
Se´bire, 1999 ▪ ^ • • •
Thomas, 2014 • • • • •
Vaccination against herpesviruses (e.g. zostavax vaccine)
Baxter, 2012 • • • • •
Kovac, 2018 • • • • •
Tseng, 2012 • • • • •
Donahue, 2009 • • • • •
MacDonaled, 2018 � • • • •
(Continued)
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CMV was the only outcome for which sufficient studies were available to assess publication
bias; there was no evidence of publication bias (see S6 Fig).
One case-control study assessed the association between HHV-6 and stroke; no association
was found.[58] Four case-control studies examined the association between EBV and stroke
(Table 1);[50, 51, 53, 55] three were hospital-based among older adults and one a multi-country
study among children (under 18 years). All studies were small (N<500) and at high-risk of bias.
There was no evidence that past infection (IgG seropositivity) was associated with stroke
risk, when combining data from three studies (summary estimate: 1.28, 95%CI:0.89–1.84;
I2<0.001) (Fig 4). The study among children found no evidence that recent infection/reactiva-
tion of EBV (measured from IgM seropositivity) was associated with stroke risk (OR 1.44, 95%
CI 0.12–16.75).
There was very low quality evidence of no association between past infection and an
increased risk following recent infection/reactivation with EBV and stroke; the quality of evi-
dence was downgraded due to high-risk of bias and imprecise estimates.
Associations between HSV-1 or HSV-2 and stroke risk were explored in seven studies[50–
54, 56, 57] (Table 1) using population survey data and an RCT, and data from a hospital set-
ting. A high-risk of bias was identified in all seven studies. No clear patterns were observed,
although there was some indication that recent HSV1 infection/reactivation (IgM seropositiv-
ity or IgA high titre) was associated with increased stroke risk.
Two case-control studies[51, 59] and one US-community based cohort study[57] assessed
the effect of serologically-defined VZV infection on stroke risk (Table 1). Past infection (IgG
seropositivity or high titre) was not associated with stroke risk in two studies (Fig 4); quality of
evidence was graded very low due to a high-risk of bias. However, a multi-country case-control
study among children (under 18 years) found recent infection/reactivation (IgM seropositiv-
ity) was associated with increased stroke risk; quality of evidence was graded as low, because
although there was a high-risk of bias, the association was very strong.
Varicella and the risk of stroke among children was assessed in three studies from Canada
and Europe;[60–62] a high-risk of bias was identified in 2/3 studies. Different study designs
Table 3. (Continued)
First author, publication yr Confounding Selection of participants Misclassification of variables Bias due to missing data Reverse Causation
Multiple herpesviruses infections
Al-Ghamdi, 2012 (HSV-1, CMV, EBV) ^ ^ • • �
Elkind, 2010 (CMV, HSV1 and HSV2) • • ▪ � •
Elkind, 2016 (HSV1/2, CMV, EBV, VZV) • ▪ • • ^
Kis, 2007 (HSV-1, CMV, EBV and HHV-6) ▪ ▪ • • ^
Li, 2005 (CMV, HSV1 and HSV2) ^ ^ • • ^
Ozturk, 2013 (CMV, EBV) ▪ ^ • • ^
Ridker, 1998 (CMV, HSV1/2) • ^ • � •
Sealy-Jefferson, 2013 (CMV, HSV1 and
VZV)
• • ^ • •
Yen, 2017 (HZ and CMV disease) • • • • •
Key
^ High risk
▪Moderate risk
• Low risk
� Unclear risk
https://doi.org/10.1371/journal.pone.0206163.t003
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Table 4. Assessment of quality of evidence for outcomes.
Quality assessment Quality
№ of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
VZV: reactivation (herpes zoster)
17 observational studies not serious not serious a not serious serious b strong association ⊕⊕⊕◯
dose response gradient MODERATE
CMV: past infection
14 observational studies serious c not serious d not serious serious b none ⊕◯◯◯
VERY LOW
CMV: recent infection/reactivation
11 observational studies serious c serious e not serious serious b strong association ⊕◯◯◯
VERY LOW
HHV6: infection/reactivation
1 observational studies very serious j not serious not serious very serious b none ⊕◯◯◯
VERY LOW
EBV: past infection
4 observational studies serious f not serious g not serious serious b none ⊕◯◯◯
VERY LOW
EBV: recent infection/reactivation
1 observational studies very serious h not serious g not serious very serious b none ⊕◯◯◯
VERY LOW
HSV-1: past infection
4 observational studies not serious i serious e not serious serious b none ⊕◯◯◯
VERY LOW
HSV-1: recent infection/reactivation
2 observational studies serious h serious e not serious serious b strong association ⊕◯◯◯
VERY LOW
HSV-2: past infection
1 observational studies not serious not serious not serious serious b none ⊕◯◯◯
VERY LOW
HSV-2: recent infection/reactivation
1 observational studies very serious j not serious not serious serious b none ⊕◯◯◯
VERY LOW
HSV-1/2: past infection
2 observational studies serious k not serious g not serious serious b none ⊕◯◯◯
VERY LOW
HSV-1/2: recent infection/ reactivation
1 observational studies serious k not serious not serious serious b none ⊕◯◯◯
VERY LOW
VZV infection, serologically defined: past infection
2 observational studies serious k not serious g not serious not serious none ⊕◯◯◯
VERY LOW
VZV infection, serologically defined: recent infection/ reactivation
1 observational studies serious k not serious not serious serious b very strong association ⊕⊕◯◯
LOW
VZV infection, clinically defined (varicella—adults)
1 observational studies not serious not serious not serious serious b strong association ⊕⊕◯◯
LOW
VZV infection, clinically defined (varicella—children)
(Continued)
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and time periods during which stroke was recorded were used, therefore estimates were not
pooled. However, each study found varicella was associated with a greater risk of stroke within
a year from diagnosis. Because of the dose-response gradient over time and very strong associ-
ations observed, the evidence was classified as moderate quality.
The SCCS study also assessed the association among adults; an increased risk of stroke
within 6-months of varicella was found (IR2.13, 95%CI:1.05–4.34). Although this association
was strong, the confidence interval was wide, thus the evidence was graded low quality.
Five studies evaluated the short-term effect of VZV vaccination on stroke risk, by compar-
ing vaccinated with unvaccinated people (or person time in the same individuals). One was a
multi-country RCT[63] and the others used Canadian or US electronic healthcare records
(Table 1);[64–67] these studies were at very low-risk of bias. No decreased risk of stroke in
those vaccinated against varicella or zoster was noted (Fig 4); evidence across studies was
graded very low and low quality for varicella and zoster vaccination, respectively.
One small (N = 111) case-control study among older hospitalised patients found no associa-
tion between HHV-6 IgG seropositivity and stroke (Table 1), in unadjusted analysis (OR 0.90,
95%CI:0.41–1.98).[53] No studies assessed herpesvirus-7 or 8.
Discussion
Our review identified 48 studies assessing the association between infection with or reactiva-
tion of herpesviruses and risk of stroke. Consistent with previous reviews, there was moderate
quality evidence that zoster was associated with a short-term increased risk of stroke, and that
increased risk was greatest shortly after zoster (decreasing to baseline by around one year).
Some evidence suggested the risk was greater among ophthalmic zoster patients, younger age
Table 4. (Continued)
3 observational studies serious l not serious g not serious serious b very strong association ⊕⊕⊕◯
dose response gradient MODERATE
Varicella vaccination
2 observational studies not serious not serious not serious very serious b none ⊕◯◯◯
VERY LOW
Herpes zoster vaccination
3 observational studies not serious not serious g not serious not serious none ⊕⊕◯◯
LOW
Explanations
a. None of meta-analyses suffered from considerable heterogeneity and trend of effects were very clear across studies using different study designs.
b. Wide confidence interval(s)
c. <50% studies have two or more domains at high risk of bias and contribute<50% weight to the meta-analysis
d. Some point estimates across studies in different directions, some overlap of confidence intervals, where meta-analyses were possible I2 statistic indicates substantial
heterogeneity (although subgroup analyses demonstrated heterogeneity was driven by a single study).
e. Some variance of point estimates across studies (yet the majority are in the in same direction), some overlap of confidence intervals, where meta-analyses were
possible I2 statistic indicates statistical heterogeneity (yet only very few studies included in meta-analyses).
f. �50% studies have two or more domains at high risk of bias, however contribute <50% weight to the meta-analysis
g. Some variance of point estimates across studies, confidence intervals overlap, no statistical evidence of heterogeneity
h. Study/studies suffered from two or more domains at high risk of bias.
i. 1/4 studies suffered from two domains at high risk of bias; this study only contributed 5% weight to the meta-analyses.
j. Study may have suffered from three domains at high risk of bias: confounding, reverse causality, and selection bias
k. Study/studies had one domain at high risk of bias.
l. 2/3 studies suffered from 2 or more domains at high risk of bias, however one study had a very low risk of bias
https://doi.org/10.1371/journal.pone.0206163.t004
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Fig 2. Effect of clinically diagnosed herpes zoster on stroke risk by study design and length of follow-up. †Outcome was ischaemic stroke ‡Outcome was stroke/
TIA μ: among patients 50–60 years of age. •Study population was immunosuppressed �Comparator group was person time 366-730days after HZ.
https://doi.org/10.1371/journal.pone.0206163.g002
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Fig 3. Effect of CMV (serological evidence of infection or clinical reactivation) on stroke risk. †Outcome was ischaemic stroke ‡Outcome was stroke/TIA •Study
population was immunosuppressed. !!No age adjustment/matching for age.
https://doi.org/10.1371/journal.pone.0206163.g003
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Fig 4. Effect of EBV, HSV, VZV infection, clinically diagnosed varicella and VZV vaccination on stroke risk. †Outcome was ischaemic stroke ‡Outcome was stroke/
TIA !!No age adjustment/matching for age.
https://doi.org/10.1371/journal.pone.0206163.g004
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groups and patients not prescribed antivirals. Moderate quality evidence suggests varicella was
associated with increased stroke risk in children. Similar to findings for VZV, there may also
be an increased stroke risk with recent CMV and HSV infection/reactivation, however the evi-
dence was very low quality. Finally, there might be an increased stroke risk associated with
recent CMV infection or reactivation based on studies carried out in immunosuppressed
populations.
Two main pathophysiological mechanisms are proposed by which herpesviruses may
increase stroke risk. Systemic infection with, or reactivation of, herpesviruses induces acute
inflammation,[2] which may lead to endothelial dysfunction accompanied by disruption of
atheromatous plaques and hypercoagulability.[68] This biological hypothesis is consistent with
our finding that latent herpesvirus infection (that is, presence of viral DNA in host cells with-
out producing infectious viral particles)[69] does not appear to increase stroke risk, as latent
infection does not cause acute inflammation in host cells. Herpesviruses may also directly
invade cerebral arteries, producing vasculopathy, leading to increased stroke risk;[70] this
could explain why younger individuals, normally free from traditional vascular risk factors,
were at higher risk of stroke following a recent infection/reactivation of VZV. VZV is the only
virus with clear evidence of virus DNA in cerebral arteries; the stronger association between
ophthalmic zoster and stroke also supports this hypothesis. CMV is associated with vasculopa-
thy in immunocompromised patients, however the mechanism, and the risk in immunocom-
petent subjects are unclear.[71]
A larger effect of zoster on stroke risk was identified in people aged below 40 years. This has
also been reported in a Korean-based cohort study. However, the absolute risk of stroke is low
in younger ages, so a large relative effect may be small in absolute terms. This finding, together
with the clinical efficacy of the currently available zoster vaccine becoming limited beyond 5–8
years,[72, 73] means vaccinating younger age groups may not be cost-effective.
This is the first study to systematically review the literature on all eight human herpesviruses
as stroke risk factors and the results are broadly in-line with previous review assessing individ-
ual herpesviruses and cardiovascular disease (including stroke risk).[3–8, 10] Strengths
included: following a pre-specified protocol; undertaking a comprehensive search; using articles
published in any language; and carrying out a complete risk of bias assessment for each study
and an assessment of the accumulated evidence using GRADE. Most studies ascertained stroke
from pre-existing health care records (n = 33/41), potentially leading to similar stroke defini-
tions across studies. A further strength of this review is that it not only included studies of clini-
cally apparent herpesviruses reactivation, but subclinical reactivation. A further strength of this
review is that it not only included studies of clinically apparent herpesviruses reactivation, but
subclinical reactivation. It is possible that those with clinical manifestations of reactivated infec-
tion (e.g. zoster), or those who are immunosuppressed (as in some CMV studies), may have
higher viral titres which plausibly could affect the risk of short term triggering of stroke.
However, limitations included having little data from low-income countries, which make
up around 75% of stroke deaths worldwide;[74] whether different populations have different
susceptibilities to stroke following herpesvirus infections is unclear. Some meta-analyses com-
bined very few studies, limiting the strength of our pooled results. Overall, the quality of evi-
dence for CMV, EBV and HSV was low or very low.
The studies of VZV, particularly zoster, were well-powered to assess the association
between VZV and stroke and rarely suffered from a high-risk of bias; however, subgroup anal-
yses were underpowered, limiting confidence in the findings. Studies of the other herpesvi-
ruses (CMV, EBV and HSV) had more limitations; many had small sample sizes, inadequate
adjustment for confounders In addition to this, the majority of non-VZV studies relied on lab-
oratory, rather than clinical, identification of possible recent infection or reactivation. The
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strength of the evidence for zoster and stroke risk lies in the studies all using clear clinical diag-
noses of reactivated VZV, which was recorded prior to stroke. In contrast to VZV infection or
reactivation which presents with clear clinical symptoms, other herpesviruses may reactivate
without any clinical symptoms. Studies that measured markers of infection after stroke may
suffer from reverse causality (all but one cases-control study–see Table 3) herpesvirus expo-
sures were defined following stroke and stroke may trigger stress, leading to detection of her-
pesviruses reactivation after 24 hours (and blood samples were rarely taken immediately after
stroke). This may explain why CMV IgG high (versus low) titre was associated with increased
stroke risk in most case-control studies,[18] but not cohort studies (in which CMV antibodies
were recorded prior to stroke). However, most case-control studies used hospital-based con-
trols, so any stress associated with hospitalisation itself may affect cases and controls equally.
In terms of future research, high-powered cohort or SCCS studies assessing the association
between recent infection with, and reactivation of, herpesviruses (aside from VZV), ideally col-
lecting serology samples regularly during follow-up are needed. Furthermore, as zoster vacci-
nation uptake increases, better-powered studies could confirm our findings that vaccination is
not associated with a short-term increased stroke risk, and establish whether the vaccine
reduces the long-term risk of stroke.
In terms of clinical practice, this review indicated that antivirals might attenuate stroke risk
among zoster patients. As patients with more severe zoster are more likely to get antivirals,
and also potentially more likely to have a stroke, this might have led to underestimation of
their effect through confounding by indication. Antiviral drugs shorten zoster healing time
and reduce pain severity[75] therefore these drugs may plausibly reduce stroke risk, by reduc-
ing inflammation. Antivirals for zoster are under-prescribed in UK primary care[76] and this
review strengthens the argument for better adherence to prescribing guidelines.
Our review highlights that we have a good understanding of a short-term increased stroke
risk following VZV infection and reactivation. It also suggests infection and reactivation of
other herpesviruses may increase stroke risk, yet better evidence is required. Herpesviruses are
common, therefore improved understanding of whether they increase the risk of stroke could
provide additional strategies for stroke prevention.
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